Sandoz Reports Q1 2025 Net Sales
Sandoz, a pharmaceutical company, has released its Q1 2025 net sales figures, which align with company expectations.
Key Financial Metrics
- Net sales: reported in line with company expectations
- Last closing stock price: 36.71 CHF
- 52-week high: 45.1 CHF
- 52-week low: 26.25 CHF
Financial Ratios
- Price-to-earnings ratio: -24640
- Price-to-book ratio: 2.29
Market Analysis
These financial ratios indicate a significant deviation from industry norms, warranting further analysis to understand Sandoz’s financial performance and market positioning.